Yervoy (ipilimumab) / BMS 
Welcome,         Profile    Billing    Logout  
 197 Diseases   398 Trials   398 Trials   21826 News 


«12...2829303132333435363738...266267»
  • ||||||||||  YH006 / Biocytogen
    YH006, a fully human Treg-depleting CTLA-4 (Exhibit Hall B) -  Sep 27, 2023 - Abstract #SITC2023SITC_1477;    
    YH006 has consistent quality from research cell bank (RCB) to passage 97. Conclusions YH006 demonstrated superior anti-tumor efficacy across several tumor models and excellent physiochemical properties, which make it a promising candidate for further development as a cancer treatment.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Nivolumab plus ipilimumab in anti-PD(L)-1 na (Exhibit Hall B) -  Sep 27, 2023 - Abstract #SITC2023SITC_1214;    
    Conclusions YH006 demonstrated superior anti-tumor efficacy across several tumor models and excellent physiochemical properties, which make it a promising candidate for further development as a cancer treatment. Among those who received prior targeted therapy, sorafenib, lenvatinib, and regorafenib were administered in 34...7% (10/23) of patients had prior anti-PD(L)-1 treatment, with nivolumab, pembrolizumab, atezolizumab + bevacizumab, and durvalumab administered in 47...Conclusions Nivolumab combined with ipilimumab demonstrated greater effectiveness in anti-PD(L)-1 na
  • ||||||||||  Evofosfomide potentiates the efficacy of a novel anti-PD-L1/PD-L2 monoclonal antibody against immune excluded tumors (Exhibit Hall B) -  Sep 27, 2023 - Abstract #SITC2023SITC_1180;    
    Background Evofosfamide (Evo) is a hypoxia-activated prodrug of the cytotoxin bromo-isophosphoramide mustard...1 Moreover, in a phase 1 clinical trial, the combination of Evo with the anti-CTLA-4 Ipilimumab resulted in objective responses in patients with cold tumors...Conclusions These data indicate that Evo and IMGS-001 in combination improves upon the efficacy of either treatment alone, and those improvements are not observed for Evo in combination with anti-PD-1 treatment. This novel combination treatment will continue to be tested in preclinical models and has potential to be tested in a clinical trial.
  • ||||||||||  ADG126 / Adagene, Yervoy (ipilimumab) / Ono Pharma, BMS
    Optimal dose selection of ADG126 (a masked anti-CTLA-4 SAFEbody (Exhibit Hall B) -  Sep 27, 2023 - Abstract #SITC2023SITC_1174;    
    3 4 The two models predict optimal dosing regimens, which warrant further clinical investigation to unleash the full therapeutic potential of ADG126 within targeted toxicities. Conclusions The continuously widened TI from ADG116 to ADG126 enables ADG126 to be dosed at 10 mg/kg Q3W and likely higher with anti-PD-1, resulting in significantly higher and sustained tumor target engagement than ipilimumab, potentially translating to greater clinical benefits.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    High-throughput screening of cancer immunotherapy combinations using a hydrogel-based 3D in vitro tumor platform (Exhibit Hall B) -  Sep 27, 2023 - Abstract #SITC2023SITC_1169;    
    2 We also observed that dosing kinetics and immune cell density dictated the degree of response for each agent compared to their combination. Conclusions The Cypre 3D platform is a broadly encompassing tool capable of exploring novel combinations that alter multiple mechanisms of immune response.
  • ||||||||||  Mekinist (trametinib) / Novartis, BeiGene, Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Combined immunotherapy improves outcome for replication repair deficient (RRD) high-grade glioma failing anti-PD1 monotherapy: a report from the International RRD consortium (Exhibit Hall B) -  Sep 27, 2023 - Abstract #SITC2023SITC_1113;    
    Treatment after progression on anti-PD1 monotherapy included re-irradiation where feasible, and continuation of anti-PD1 with either anti-CTLA4 (ipilimumab), or a MEK-inhibitor (trametinib)...The combination of ipilimumab/nivolumab (n=24) resulted in response/stable disease in 75%, with median OS2 of 12...The combination with re-irradiation and additional immune/targeted agents can maximize survival in these children and young adults. Future research should focus on biology-driven rational immunotherapy combinations that also result in lower toxicity to maximize patient benefit.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Dissecting pancreatic cancer tumor-immune microenvironment crosstalk using spatial transcriptomics (Exhibit Hall B) -  Sep 27, 2023 - Abstract #SITC2023SITC_992;    
    P2
    14 A randomized multi-institutional clinical trial of FOLFIRINOX +/- losartan +/- nivolumab (anti-PD1) for PDAC has been completed (NCT03563248)...15 A pilot trial demonstrated a 29% disease control rate with combined nivolumab + ipilimumab and radiation therapy...Conclusions Spatial transcriptomics and proteomics reveal insights into the spatial relationship between PDAC tumor cell EMT plasticity, CAFs, and immune infiltrates. This enables the discovery of novel immune response biomarkers and potential therapeutic avenues to target tumor and microenvironment interactions.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    A case series of neoadjuvant ipilimumab and nivolumab in 2 patients with locoregional mucosal melanoma (Exhibit Hall B) -  Sep 27, 2023 - Abstract #SITC2023SITC_915;    
    Conclusions These cases provide support that a subset of patients with locoregional mucosal melanoma may benefit from neoadjuvant immunotherapy. Further prospective studies should be done to compare outcomes, including rates of tumor recurrence, between neoadjuvant immunotherapy and conventional wide local surgical resection.
  • ||||||||||  A systematic review of anti-drug antibodies related to CTLA-4, PD-1 or PD-L1 inhibitors across tumour types (Exhibit Hall B) -  Sep 27, 2023 - Abstract #SITC2023SITC_910;    
    The incidence of neutralising antibodies (nAbs) mirrored ADA distribution, being highest for atezolizumab (4...Emergence of nAbs follows but does not perfectly mirror ADA titers, raising questions around the functional meaning of different ADAs. Standardised reporting of ADAs and nAbs should be advocated to facilitate more conclusive immunologic and clinical insight as to the relationship with ADAs and response.
  • ||||||||||  Yervoy (ipilimumab) / Ono Pharma, BMS
    Development of a tri-specific antibody targeting PD-1/CTLA-4/TIGIT (Exhibit Hall B) -  Sep 27, 2023 - Abstract #SITC2023SITC_848;    
    The anti-CTLA-4 arm only partially blocks the binding of CTLA-4 to its ligands, resulting in better in vivo tolerability than ipilimumab...GBD209 may profoundly provoke anti-tumor immunity and overcome PD-1 resistance in patients. The tri-specific modality and unique design of GBD209 may represent a novel and effective therapeutics for cancer treatment.
  • ||||||||||  napabucasin (BBI608) / Sumitomo Pharma, Yervoy (ipilimumab) / Ono Pharma, BMS
    Generation of an innovative bispecific antibody targeting CCR8/CTLA4 (Exhibit Hall B) -  Sep 27, 2023 - Abstract #SITC2023SITC_847;    
    The bsAb has been fine tuned to reduce the peripheral toxicity associated with CTLA-4 blockade. GBD201 may present a novel immunotherapy approach to direct CTLA-4 inhibition or Treg depletion within the tumor microenvironment, and improve clinical benefits of other anti-cancer agents such as PD-1 inhibitors or ADCs in the treatment of cancers.
  • ||||||||||  A novel antagonist monoclonal antibody against human adenosine receptor 2a (A2aR) for cancer immunotherapies (Exhibit Hall B) -  Sep 27, 2023 - Abstract #SITC2023SITC_834;    
    Furthermore, it showed significant synergistic effect on inhibiting tumor growth when combined with Ipilimumab, Opdivo or Avastin, through multiple mechanisms including reduced ratios of Tregs:CD8+ T cells within the tumor microenvironment. Conclusions The antagonist A2aR antibody represents a promising novel therapeutic candidate to potentiate combinatorial approaches for cancer immunotherapy via enhancing anti-tumor responses in solid tumors that only partially respond or are completely resistance to ICB therapies due to elevated adenosine level in tumor microenvironment.
  • ||||||||||  Safety of immune checkpoint inhibitors in cancer patients with HIV  (Exhibit Hall B) -  Sep 27, 2023 - Abstract #SITC2023SITC_809;    
    Conclusions Our study demonstrates that HIV patients who receive ICI treatment have similar risk of irAE compared to non-HIV patients, indicating that ICI treatment is safe in this population. Eligibility criteria for clinical trials should be expanded to include HIV patients to improve health outcomes in this population.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Exploring the relationship between tumour heterogeneity and response to immunotherapy in malignant pleural mesothelioma (Exhibit Hall B) -  Sep 27, 2023 - Abstract #SITC2023SITC_546;    
    P1/2
    Conclusions This pilot analysis provides valuable insights into the tumour-based molecular signatures associated with the response to IPI + NIVO therapy in MPM patients. The ongoing recruitment in NCT04631731 holds promise for successful validation of preliminary data thus providing new perspectives on establishing risk factors of ICI therapy in near future.
  • ||||||||||  Yervoy (ipilimumab) / Ono Pharma, BMS
    Unveiling the diversity in melanoma immunotherapy response biomarkers between lymph node and non-lymph node biopsies (Exhibit Hall B) -  Sep 27, 2023 - Abstract #SITC2023SITC_480;    
    Methods Two consecutive slides from pretreatment biopsies of 47 melanoma patients who received PD-1 blockade, as a single-agent, or combined with ipilimumab, were collected and stained with two 6-plex mIF antibody panels using PhenoImager, followed by hematoxylin and eosin (H& E) stain on the same slide (figure 1)...Conclusions Our study demonstrates that the tumor-microenvironment in LN and non-LN melanoma biopsies exhibits distinct spatial characteristics associated with immunotherapy response. These findings highlight the importance of spatial features, cell composition, and biopsy site when identifying spatial biomarkers for immunotherapy response prediction.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Application of novel AI-assisted technology in 18F-FDG PET-CT scan analysis  (Exhibit Hall B) -  Sep 27, 2023 - Abstract #SITC2023SITC_451;    
    Conclusions This study demonstrates that an AI-assisted immunotherapy response analysis can help predict disease response using quantitative features from 18F-FDG PET-CT imaging of patients with metastatic melanoma undergoing immunotherapy. These results support further investigation into individual outcomes, type of immunotherapy and warrants future studies to validate these findings in a prospective cohort.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Journal:  Management Strategies and Outcomes in Primary Liver Angiosarcoma. (Pubmed Central) -  Sep 26, 2023   
    However, most patients present with advanced disease and are not surgical candidates. Further research is needed to identify more effective systemic therapy options for this devastating disease.
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Trial completion date, Trial primary completion date:  BTCRC LUN 16-081: Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) -  Sep 26, 2023   
    P2,  N=105, Active, not recruiting, 
    Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Sep 2023 --> Sep 2024 Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Aug 2023 --> Dec 2023
  • ||||||||||  Leukine (sargramostim) / Partner Therap, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Trial completion date, Trial primary completion date:  A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma (clinicaltrials.gov) -  Sep 26, 2023   
    P2/3,  N=600, Recruiting, 
    Trial completion date: Aug 2023 --> Aug 2025 | Trial primary completion date: Aug 2023 --> Aug 2025 Trial completion date: Aug 2023 --> Jun 2033 | Trial primary completion date: Aug 2023 --> Jun 2033
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Trial completion, Trial completion date, Trial primary completion date:  Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs (clinicaltrials.gov) -  Sep 26, 2023   
    P2,  N=29, Completed, 
    Trial completion date: Aug 2023 --> Jun 2033 | Trial primary completion date: Aug 2023 --> Jun 2033 Active, not recruiting --> Completed | Trial completion date: Jan 2024 --> Sep 2023 | Trial primary completion date: Jan 2024 --> Sep 2023